MONOCLONAL ANTIBODIES SPECIFIC FOR FIBROBLAST GROWTH FACTOR RECEPTOR 4 (FGFR4)AND METHODS OF THEIR USE Read more about MONOCLONAL ANTIBODIES SPECIFIC FOR FIBROBLAST GROWTH FACTOR RECEPTOR 4 (FGFR4)AND METHODS OF THEIR USE Canada3289997Filed on 2025-10-22
Chimeric Antigen Receptors Containing Glypican 2 Binding Domains Read more about Chimeric Antigen Receptors Containing Glypican 2 Binding Domains MacaoJ/009659Filed on 2020-07-17
SMALL CELL LUNG CANCER SUBTYPING USING PLASMA CELL-FREE NUCLEOSOMES Read more about SMALL CELL LUNG CANCER SUBTYPING USING PLASMA CELL-FREE NUCLEOSOMES European Patent23807180.7Filed on 2024-12-17
SMALL CELL LUNG CANCER SUBTYPING USING PLASMA CELL-FREE NUCLEOSOMES Read more about SMALL CELL LUNG CANCER SUBTYPING USING PLASMA CELL-FREE NUCLEOSOMES US Application 18/865,855Filed on 2024-11-14
T CELL RECEPTORS RECOGNIZING MUTATED P53 Read more about T CELL RECEPTORS RECOGNIZING MUTATED P53 European Patent25200391.8Filed on 2025-09-05
HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12R MUTATION Read more about HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12R MUTATION US Application 19/334,152Filed on 2025-09-19
Chimeric Antigen Receptors Targeting B-cell Maturation Antigen Read more about Chimeric Antigen Receptors Targeting B-cell Maturation Antigen European Patent25206361.5Filed on 2025-10-02
ENGINEERED RNA DEVICES IN HUMAN T-CELLS TO CONTROL GENE EXPRESSION EXTERNALLY Read more about ENGINEERED RNA DEVICES IN HUMAN T-CELLS TO CONTROL GENE EXPRESSION EXTERNALLY Patent Cooperation TreatyPCT/US2025/042148Filed on 2025-08-15
METHODS FOR ENHANCING THE IMMUNOGENICITY OF CELLULAR VACCINES Read more about METHODS FOR ENHANCING THE IMMUNOGENICITY OF CELLULAR VACCINES Patent Cooperation TreatyPCT/US2024/022230Filed on 2024-03-29
Peptide-pulsed MHC class II semi-allogeneic dendritic cell vaccine induces more efficacious anti-tumor responses Read more about Peptide-pulsed MHC class II semi-allogeneic dendritic cell vaccine induces more efficacious anti-tumor responses US Application 63/456,176Filed on 2023-03-31